Search

Now showing items 1-10 of 120

Long-term comparison of anastrozole versus tamoxifen: Results from LATTE/ATAC

Cuzick, J; Sestak, I; Bianco, A; Strobbe, L; Bergh, J; Hanusch, C; Neven, P; Dowsett, M; Forbes, JF; Buzdar, A;... (2017-02)

Comprehensive comparison of prognostic signatures for breast cancer in TransATAC

Sestak, I; Buus, R; Cuzick, J; Dubsky, P; Kronenwett, R; Ferree, S; Sgroi, D; Schnabel, C; Baehner, R; Mallon, E;... (2017-02)

Progress in breast cancer prevention

Cuzick, J (2014-07)

Atypical Hyperplasia of the Breast

Brentnall, AR; Cuzick, J (2015-03-26)

Preventing invasive breast cancer in women at high risk based on benign/in situ pathology

Cuzick, J; Thorat, M (2015-03)

Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast Cancer

Dowsett, M; Sestak, I; Buus, R; Lopez-Knowles, E; Mallon, E; Howell, A; Forbes, JF; Buzdar, A; Cuzick, J (2015-06-15)

Progesterone receptor A predominance is a discriminator of benefit from endocrine therapy in the ATAC trial

Mote, PA; Gompel, A; Howe, C; Hilton, HN; Sestak, I; Cuzick, J; Dowsett, M; Hugol, D; Forgez, P; Byth, K;... (2015-06)

Relationship of ZNF423 and CTSO with breast cancer risk in two randomised tamoxifen prevention trials

Brentnall, AR; Cuzick, J; Byers, H; Segal, C; Reuter, C; Detre, S; Sestak, I; Howell, A; Powles, TJ; Newman, WG;... (2016-08)

Retrospective analysis of molecular scores for the prediction of distant recurrence according to baseline risk factors

Sestak, I; Dowsett, M; Ferree, S; Baehner, FL; Cuzick, J (2016-08)

Use of the concordance index for predictors of censored survival data.

Brentnall, AR; Cuzick, J (2016-11-08)

The concordance index is often used to measure how well a biomarker predicts the time to an event. Estimators of the concordance index for predictors of right-censored data are reviewed, including those based on censored ...

1
2
3
4
. . .
12